Ramachandra Sumant
SEC CIK 1439368 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | Dir | 200.0K | $116.0K | — | 1 | 2025-03-21 | 2025-03-21 |
Most active insiders at LYEL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ARCH Venture Partners IX Overage, L.P. | 10% | $12.50M | — |
| 2 | BERNS PAUL L | 10% | $12.50M | — |
| 3 | Seely Lynn | Pres, CEO, Dir | — | $353.1K |
| 4 | Bulis Veronica Sanchez | VP, Corp. Ctrl | — | $96.9K |
| 5 | Lee Gary K. | CSO | — | $71.7K |
| 6 | Hill Stephen J. | COO | — | $51.3K |
| 7 | Shook David | Chief Medical Off | — | $31.3K |
| 8 | Innovative Cellular Therapeutics Holdings Ltd | 10% | — | $274.30 |
Ramachandra Sumant made no open-market trades at LYEL in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-03-25 | 2025-03-21 | LYEL | Lyell Immunopharma, Inc. | Ramachandra Sumant | Dir | P - Purchase | $0.58 | +200.0K | 200.0K | New | +$116.0K |
Purchase Sale Sale after option exercise All abbreviations